PolyMedix Receives Patent for Compounds for Angiogenesis Inhibitors
July 21, 2009
PolyMedix, Inc. has announced the United States Patent and Trademark Office has issued a patent for the company related to their angiogenesis inhibitors. The patent, number 7,553,876, entitled “Polycationic Compounds and Uses Thereof,” relates to therapeutic uses of PolyMedix compounds for inhibiting angiogenesis.
PolyMedix’s angiogenesis inhibitors may have a mechanism of action distinct from compounds that only inhibit VEGF (vascular endothelial growth factor). These inhibitors may be helpful in the treatment of macular degeneration. The patent states that PolyMedix’s invention relates to “compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound.”
PolyMedix is a publicly traded biotechnology company that is focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders.
Read the complete press release and the patent information.
You might also enjoy...
- Stemedica Applies for Patent Application for Diabetic Retinopathy Treatment
- MacuSight’s Perceiva May Treat Diabetic Macular Edema and Wet Macular Degeneration
- Lux Biosciences Completes Patient Enrollment in LUCIDA Phase 3 Program for LUMITECT for Prevention of Corneal Transplant Rejection
- Santen and Merck Sign Licensing Agreement for Tafluprost Treatment for Glaucoma and Ocular Hypertension
- Resolvyx Pharmaceuticals Presentations at ARVO 2009
Comments
Jump down to form below to submit your own comments
